RPG-I: The Influence of Rumex Acetosa L on the Intraoral Colonization With Porphyromonas Gingivalis

Sponsor
Heinrich-Heine University, Duesseldorf (Other)
Overall Status
Completed
CT.gov ID
NCT02039648
Collaborator
(none)
35
1
2
13
2.7

Study Details

Study Description

Brief Summary

Periodontitis is a biofilm depended oral infection. It leads to inflammatory destruction of periodontal tissues and if left untreated to tooth loss. Porphyromonas gingivalis (P.g.) is one of the major pathogens associated with the onset and progression of periodontitis. Previous in vitro studies have shown that a proanthocyanidin-enriched extract from Rumex acetosa L. inhibits the adhesion of P.g. and acts in a cytoprotective manner. Since the the bacterial adhesion to oral mucosa cells is a pivotal step for the P.g. mediated tissue destruction, its inhibition may be helpful in preventing the colonization with P.g. or its eradication in P.g. infected patients. Therefore, the aim of this controlled, randomized and double blinded study was to analyze the effects of a Proanthocyanidin-enriched extract from Rumex acetosa L. on the intraoral colonization with Porphyromonas gingivalis in individuals harboring P.g. intramurally.

Condition or Disease Intervention/Treatment Phase
  • Other: Rumex acetosa L. extract
  • Other: Placebo
Early Phase 1

Detailed Description

During screening phase plaque samples of healthy individuals were tested via polymerase chain reaction for the prevalence of P.g..

At baseline those identified P.g. positive participants received a supragingival debridement (professional tooth cleaning) and were randomly assigned to the test- or control-group. Afterwards the study participants are instructed to rinse 3 times per day with 10 ml of either Rumex acetosa L. extract mouth rinse or the placebo mouth rinse for 7 days in addition to their oral hygiene procedures. Plaque samples were taken at different visits (screening, baseline, 2, 4, 7 and 14 days after baseline) and P.g. was identified and quantified by real-time polymerase chain reaction (qrt-PCR). Also the relative quantity of eight other oral pathogenic microorganisms (Aggregatibacter actinomycetemcomitans, Treponema denticola, Tannerella forsythia, Prevotella nigrescens, Prevotella intermedia, Eikenella corrodens, Streptococcus mutans and Candida albicans) and four commensal bacteria (Streptococcus sanguinis, Streptococcus mitis, Veillonella parvula and Actinomyces viscosus) was determined over the whole study period by qrt-PCR. Additionally clinical parameters, i.e. the Approximal Plaque Index (API) and the modified Sulcular Bleeding Index (SBI) were recorded at baseline, 7 and 14 days. For identifying any dysplastic changes and mutations as a potential reaction to the tested mouthwash solutions brushing biopsies of the oral mucosa were taken at baseline and day 7 and were histologically examined.

Study Design

Study Type:
Interventional
Actual Enrollment :
35 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Prevention
Official Title:
Proanthocyanidin- Enriched Extract From Rumex Acetosa L. as a Prophylactic Agent Against Intraoral Colonization With Porphyromonas Gingivalis
Study Start Date :
Mar 1, 2012
Actual Primary Completion Date :
Apr 1, 2013
Actual Study Completion Date :
Apr 1, 2013

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Rumex acetosa L. extract

Rumex acetosa L. extract mouthrinse, 10 ml, tid, 3 min, 7 days

Other: Rumex acetosa L. extract

Placebo Comparator: Placebo

Placebo mouthrinse, 10 ml, tid, 3 min, 7 days

Other: Placebo

Outcome Measures

Primary Outcome Measures

  1. change of the intraoral prevalence of Porphyromonas gingivalis [change from baseline to 2, 4, 7 and 14 days]

Secondary Outcome Measures

  1. change of the Approximal Plaque Index [change from baseline to 7 and 14 days]

  2. change of the Sulcular Bleeding Index [change from baseline to 7 and 14 days]

  3. change of the cytopathological appearance of the mucosal tissue [change from baseline to 7 days]

Other Outcome Measures

  1. change of the intraoral prevalence of Aggregatibacter actinomycetemcomitans [change from baseline to 2, 4,7, and 14 days]

  2. change of the intraoral prevalence of Treponema denticola [change from baseline to 2, 4, 7, and 14 days]

  3. change of the intraoral prevalence of Tannerella forsythia [change from baseline to 2, 4, 7 and 14 days]

  4. change of the intraoral prevalence of Prevotella intermedia [change from baseline to 2, 4, 7 and 14 days]

  5. change of the intraoral prevalence of Prevotella nigrescens [change from baseline to 2, 4, 7 and 14 days]

  6. change of the intraoral prevalence of Eikenella corrodens [change from baseline to 2, 4, 7 and 14 days]

  7. change of the intraoral prevalence of Streptococcus mutans [change from baseline to 2, 4, 7 and 14 days]

  8. change of the intraoral prevalence of Candida albicans [change from baseline to 2, 4, 7 and 14 days]

  9. change of the intraoral prevalence of Streptococcus sanguinis [change from baseline to 2, 4, 7 and 14 days]

  10. change of the intraoral prevalence of Streptococcus mitis [change from baseline to 2, 4, 7 and 14 days]

  11. change of the intraoral prevalence of Veillonella parvula [change from baseline to 2, 4, 7 and 14 days]

  12. change of the intraoral prevalence of Actinomyces viscosus [change from baseline to 2, 4, 7 and 14 days]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • generally healthy

  • periodontally healthy with Periodontal Screening Index ≤ 2

Exclusion Criteria:
  • antibiotic therapy within the previous 6 months

  • allergies against mouthrinse components

  • pregnancy or lactation

  • soft tissue lesions (e.g. lichen planus, leukoplakia)

  • history of periodontal disease and/ or PSI ≥ 3 or more

  • any topical or systemical medication, that potentially influence any immunological parameters

  • any systemic disease or medical condition (e.g. diabetes or immunological disorders), that potentially influence the immune response or compromise the study results

  • any systemic conditions, that require an antibiotic coverage for routine dental procedures (e.g. endocarditis)

Contacts and Locations

Locations

Site City State Country Postal Code
1 Department od Operative Dentistry, Periodontics and Endodontics Duesseldorf Germany 40225

Sponsors and Collaborators

  • Heinrich-Heine University, Duesseldorf

Investigators

  • Principal Investigator: Thomas Beikler, Prof., Heinrich-Heine-University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Heinrich-Heine University, Duesseldorf
ClinicalTrials.gov Identifier:
NCT02039648
Other Study ID Numbers:
  • NRW 300262502
First Posted:
Jan 17, 2014
Last Update Posted:
Jan 17, 2014
Last Verified:
Jan 1, 2014
Keywords provided by Heinrich-Heine University, Duesseldorf
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 17, 2014